Corticosteroids as adjunctive treatment in community-acquired pneumonia

Minerva Anestesiologica

Volumn 80, Issue 12, 2014, Pages 1336-1344

  Sibila, O ^a,b   Ferrer, M ^c,d,e   Agusti C ^c,d,e   Torres, A ^c,d,e  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Acquired infections; Community; Inflammation; Pneumonia

Indexed keywords

CORTICOSTEROID; ANTIINFLAMMATORY AGENT;

COMMUNITY ACQUIRED PNEUMONIA; CORTICOSTEROID THERAPY; DRUG MECHANISM; DRUG USE; HUMAN; HYPERGLYCEMIA; HYPERNATREMIA; METABOLIC DISORDER; MUSCLE WEAKNESS; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SECONDARY INFECTION; SUPERINFECTION; TREATMENT OUTCOME; COMMUNITY-ACQUIRED INFECTIONS; MORTALITY; PNEUMONIA;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; PNEUMONIA;

EID: 84925458660     PISSN: 03759393     EISSN: 18271596     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970-2002. JAMA 2005;294:1255-9.
2. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020:Global burden of disease study. Lancet 1997;349:1498-504.
3. Heron M, Hoyert DL, Murphy SL, et al. Deaths: final data for 2006. Natl Vital Stat Rep 2009;57:1-134.
4. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes in patients with community-acquired pneumonia. JAMA 1996;275:134-41.
5. Sibille Y, Reynolds HY. Macrophages and polymorphonuclear neutrophils in lung defense and injury. Am Rev Respir Dis 1990;141:471-501.
6. Nelson S, Bagby GJ, Bainton BG, et al. Compartimentalization of intraalveolar and systemic lipopolysaccharideinduced tumor necrosis factor and the pulmonary inflammatory response. J Infect Dis 1989;159:189-194.
7. Menendez R, Cavalcanti M, Reyes S, et al. Markers of treatment failure in hospitalized community-acquired pneumonia. Thorax 2008;63:447-52
8. Ramirez P, Ferrer M, Marti V, Reyes S, Martinez R, Menendez R et al. Inflammatory biomarkers and prediction for intensive care unit admission in severe community-acquired pneumonia. Crit Care 2011;39:2211-7.
9. Menendez R, Martinez R, Reyes S, Mensa J, Filella X, Marcos MA et al. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax 2009;64:587-91.
10. Rhen T, Cidlowsky JA. Antiinflammatory action of glucocorticoids - new mechanisms for old drugs. N Eng J Med 2005;353:1711-23.
11. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticoids. Rev Infect Dis 1989;69:954-63.
12. Conesa D, Rello J, Valles J, Mariscal D, Ferreres JC. Invasive aspergillosis: a life-threatening complication of shortterm steroid treatment. Ann Pharmacother 1995:29:1235-7.
13. Maskell NA, Waine DJ, Lindley A, Pepperell JC, Wakefield AE, Miller RF et al. Asymptomatic carriage of Pneumocystis jiroveci in subjects undergoing bronchoscopy: a prospective study. Thorax 2003;58:594-7.
14. Falguera M, Carratali J, Ruiz-Gonzalez A, Garcia-Vidal C, Gazquez I, Dorca J et al. Risk factors and outcome of community-acquired pneumonia due to Gram-negative bacilli. Respirology 2009;14:105-11.
15. Li Y, Cui X, Li X, Solomon SB, Danner RL, Banks SM et al. Risk of death do not alter the efficacy of hydrocortisone therapy in mouse E. coli pneumonia model. Intens Care Med 2008;34:568-77.
16. Sibila O, Luna CM, Agusti C, Baquero S, Gando S, Patron JR et al. Effects of glucocorticoids in ventilated piglets with severe pneumonia. Eur Respir J 2008;32:1037-46.
17. Tagliabue C, Salvatore CM, Techasaensiri C, Mejias A, Torres JP, Katz K et al. The impact of steroids given with macrolide therapy on experimental Mycoplasma pneumoniae respiratory infection. J Infect Dis 2008;32:1037-46.
18. Confalonieri R, Rubino G, Carbone A, Urbino R, Potena A, Piattella M, Parigi P, Puccio G et al. Hydrocortisone infusion for severe community-acquired pneumonia; a preliminar randomised study. Am J Respir Crit Care Med 2005;171:242-8.
19. Garcia-Vidal C, Calbo E, Pascual V, Ferrer C, Quintana S, Garau J. Effects of systemic steroids in patients with severe community-acquired pneumonia. Eur Respir J 2007;30:951-6.
20. Mikami K, Suzuki M, Kitagawa H, Kawakami M, Hirota N, Yamaguchi H et al. Efficay of corticosteroids in the treatment of community-acquired pneumonia requiring hospitalization. Lung 2007;185:249-55.
21. Meijvis S, Hardeman H, Remmelts H, Heijligenberg R, Rijkers GT, Van Velzen-Blad H et al. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomized, double-blind, placebocontrolled trial. Lancet 2011:377:2023-30.
22. Fernandez-serrano S, Dorca J, Garcia-Vidal C, Fernandez-Sabe N, Carratala J, Femandez-Agiiera A et al. Effect of corticosteroids on the clinical course of community-acquired pneumonia: a randomized controlled trial. Critical Care 2011;15:R96.
23. Sabry NA, Omar EED. Corticosteroids and ICU Course of Community Acquired Pneumonia in Egiptian Settings. Pharmacology and Pharmacy 2011;2:73-81.
24. Snijders D, Daniels JMA, De Graaff C, Van Der Werf TS, Boersma WG. Efficacy of corticosteroids in community-acquired pneumonia. A Randomised double-blinded clinical trial. Am J Respir Crit Care Med 2010;181:975-82.
25. Salluh JI, Soares M, Coelho LM, Bozza FA, Verdeal JC, Castro-Faria-Neto HC et al. Impacr of systemic corticosteroids on the clinical course and outcomes of patients with severe community acquired pneumonia: a cohort study. J Crit Care 2011;26:193-200.
26. Webster JL, Tonelli L, Sternberg EM. Neuroendocrine regulation of immunity. Annu Rev Immunol 2002;20:125-63.
27. De Bosscher K, Vanden Berghe W, Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-kappa beta or activator protein-1: molecular mechanisms for gene repression. Endocr Rev 2003;24; 488-522.
28. Barnes PJ. Corticosteroid effects on cell signaling. Eur Respir J 2006;27:413-26.
29. Hafezi-Moghadam A, Simoncini T, Yang Z, Limbourg FP, Plumier JC, Rebsamen MC et al. Acute cardiovascular protective effect of corticosteroid are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nature Med 2002;8:473-9.
30. Meduri GU, Kanagat S, Bronze M, Patterson DR, Meduri CU, Pak C et al. Effects of methylprednisolone on intracellular bacterial growth. Clin Diagn Lab Immunol 2001;8:1156-63.
31. Van Staa TP, Leukfens HGM, Abenhaim L, Begaud B, Zhang B, Cooper C. Use of oral corticosteroids in the United Kingdom. QJ Med 2000;93:105-11.
32. Chatila WM, Thomashow BM, Minai OA, Criner GJ, Make BJ. Comorbodities in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008;5:549-55.
33. Lange P, Vestbo J, Nyboe J. Risk factors for death and hospitalization from pneumonia. A prospective study of a general population. Eur Respir J 1995;8:1694-8.
34. Sliedrecht A, Den Elzen WR Verheij TJ, Westendorp RG, Gussekloo J. Incidence and predictive factors of lower respiratory tract infections among the very elderly in the general population. The Leiden 85-plus Study. Thorax 2008;63:817-22.
35. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance: United States, 1971-2000. MMWR Surveill Summ 2002;51:1-16.
36. Minino AM, Murphy SL, Xu J, Kochanek KD. Deaths: final data for 2008. Natl Vital Stat Rep 2011;59:1-126.
37. Malave A, Laserna E, Sibila O, Mortensen EM, Anzueto A, Restrepo MI. Impact of prior systemic corticosteroid use in patients admitted with community-acquired pneumonia. Ther Adv Respir Dis 2012;6:323-30.
38. Polverino E, Cilloniz C, Dambrava P, Gabarrus A, Ferrer M, Agusti C et al. Systemic corticosteroids for communityacquired pneumonia: Reasons for use and lack of benefits on outcome. Respirology 2013;18:263-71.
39. Restrepo MI, Mortensen EM, Pugh JA, Anzueto A. COPD is associated with increased mortality and severity scoring in community-acquired pneumonia. Eur Respir J 2006;28:346-51.
40. Rello J, Rodriguez A, Torres A, Roig J, Sole-Violan J, Garnacho-Montero J et al. Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia. Eur Respir J 2006;27:1210-6.
41. Molinos L, Clemente MG, Miranda B, Alvarez C, Del Busto B, Cocina BR et al. Community-aquired pneumonia in patients with and without chronic obstructive pulmonary disease. J Infect 2009;58:417-24.
42. Menendez R, Torres A, Zalacafn R, Aspa J, Martin Villasclaras JJ, Borderias L et al. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax 2004;59:960-5.
43. Torres A, Dorca J, Zalacain R, Bello S, El-Ebiary M, Molinos L et al. Community-acquired pneumonia in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996;154:1456-61.
44. Liapikou A, Polverino E, Ewig S, Cilloniz C, Marcos MA, Mensa J et al. Severity and outcomes of hospitalized community-acquired pneumonia in COPD patients. Eur Respir J 2012;39:855-61.
45. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Eng J Med 1997;336:243-50.
46. Menendez R, Torres A, Zalacain R, Aspa J, Martin Villasclaras JJ, Borderias L et al. Risk factors of treatment failure in community-acquired pneumonia: implications for disease outcome. Thorax 2004;59:960-5.
47. Torres A, Menendez R. Mortality in COPD patients with community-acquired pneumonia: who is the third partner? Eur Respir J 2006;28:262-3.
48. Wunderink RG, Mandell LA. Adjuntive therapy in community-acquired pneumonia. Semin Respir Crit Care 2012;33:311-8.
49. Gagnon S, Boota AM, Fischl MA, Baier H, Kirksey OW, La Voie L. Corticosteroids as adjuntive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: a double-blind, placebo-controlled trial. N Eng J Med 1990;323:1444-50.
50. Bozzette SA, Sattler FR, Chiu J, Wu AW, Gluckstein D, Kemper C et al. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med 1990;323:1451-7.
51. Mer M, Richards GA. Corticosteroids in life-threatening varicella pneumonia. Chest 1998;114:426-31.
52. Adhami N, Arabi Y, Raees A, Al-Shimemeri A, Ur-Rahman M, Memish ZA. Effect of corticosteroids on adult varicella pneumonia: cohort study and literature review. Respirology 2006;11:437-41.
53. Goldman M, Johnson PC, Sarosi GA. Fungal pneumonias: the endemic mycoses. Clin Chest Med 1999;20:507-19.
54. Lahm T, Neese S, Thornburg AT, Ober MD, Sarosi GA, Hage CA. Corticosteroids for blastomycosis-induced ARDS: a report of two patients and review of the literature. Chest 2008;133:1478-80.
55. Nie W, Zhang Y, Cheng J, Xiu Q. Corticosteroids in the treatment of community-acquired pneumonia in adults: A meta-analysis. Plos ONE 2012;7:e47926.
56. Confalonieri M, Annane D, Antonaglia C, Santagiuliana M, Borriello EM, Meduri GU. Is prolongued low-dose glucocorticoid treatment beneficial in community-acquired pneumonia. Curr Infect Dis Rep 2013;15:158-66.
57. Barber AE, Coyle SM, Fischer E, Smith C, Van Der Poll T, Shires GT et al. Influence of hypercortisolemia on soluble tumor necrosis factor receptor II and interleukin-l receptor antagonist responses to endotoxin in human beings. Surgery 1995;118:406-10.
58. Keh D, Boenkhe T, Weber-Cartens S, Schulz C, Ahlers O, Bercker S, Volk HD et al. Immunologic and hemodynamic effects of "low-dose" hydrocortisone in septic shock. A double blind, randomised, placebo-controlled, crossover study. Am J Respir Crit Care Med 2003;167:512-20.
59. Barber AE, Coyle SM, Marano MA, Fischer E, Calvano SE, Fong Y et al. Glucocorticoid therapy alters hormonal and cytokine responses to endotoxin in man. J Immunol 1993;150:1999-2006.
60. Annane D, Bellisant E, Bollaert PE, Briegel J, Confalonieri M, De Gaudio R et al. Corticosteroids in the treatment of severe sepsis and septic shock in adults. JAMA 2009;301:2362-75.
61. Van Der Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M. Intensin insulin therapy in the critically ill patients. N Eng J Med 2001;345:1359-67.
62. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC et al. IDSA/ATS consensus guidelines on the management of community-acquired pneumonia. Clin Infect Dis 2007;44(Suppl 2):S27-72.
63. Sprung CL, Caralisis PV, Marcial EH, Pierce M, Gelbard MA, Long WM et al. The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. N Eng J Med 1984;311:1137-43.
64. Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K et al. Hydrocortisone therapy for patients with septic shock. N Eng J Med 2008;358:111-24.
65. Bernard GR, Luce JM, Sprung CL, Rinaldo JE, Tate RM, Sibbald WJ et al. High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Eng J Med 1987;317:1565-70.
66. Meersseman W, Vandecasteele SJ, Wilmer A, Verbeken E, Peetermans WE, Van Wijngaerden E. Invasive aspergillosis in critically ill patients without malignancies. Am J Respir Crit Care Med 2004;170:621-5.
67. Martinez R, Reyes S, Menendez R. Pulmonary nocardiosis: risk factors, clinical features, diagnosis and prognosis. Curr Opin Pu Im Med 2008;14:219-27.
68. Steinberg KP, Hudson LD, Goodman RB, Hough CL, Lanken PN, Hyzy R et al. Efficay and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med 2006;354:1671-739.
69. Meduri GU, Healey S, Golden E, Carson SJ, Umberger RA, Kelso T et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome. A randomized controlled trial. JAMA 1998;280:159-65.